Use Of Highly Selective NSAID Comparator In Arcoxia Trials Remains Controversial
This article was originally published in The Pink Sheet Daily
Executive Summary
Merck’s Arcoxia should not be approved based on a comparison to diclofenac in the MEDAL studies, Cleveland Clinic’s Nissen says.
You may also be interested in...
Pfizer Will Highlight Celebrex Safety In ’07
Firm to address cardiovascular safety for the COX-2 inhibitor in a new DTC advertising campaign.
Pfizer Will Highlight Celebrex Safety In ’07
Firm to address cardiovascular safety for the COX-2 inhibitor in a new DTC advertising campaign.
Celebrex JRA Indication To Be Evaluated By FDA Advisory Committee
Lack of long-term safety data “poses a special challenge” in weighing risks and benefits, FDA says in briefing documents.